ClearPoint Neuro Inc.
CLPT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CLPT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CLPT
ClearPoint Neuro Inc. is a medical device company focused on products and services for drug delivery into the brain, with a key growth driver in supporting pharmaceutical customers' gene and cell therapy trials.
Key risk: High debt relative to equity
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
ClearPoint Neuro Inc. is a medical device company focused on products and services for drug delivery into the brain, with a key growth driver in supporting pharmaceutical customers' gene and cell therapy trials.
- Cash & equivalents of $30.3M as of 2026-06-30 [sec].
- Total revenue of $10.9M for the quarter ended 2026-06-30 [sec].
- Net loss of $11.3M for the quarter ended 2026-06-30 [sec].
- Shareholders' equity of $19.7M and total debt of $50.2M as of 2026-06-30 [sec].
- The biologics and drug delivery segment, serving pharma customers in gene and cell therapy trials, is described as the largest potential growth opportunity [sec_mda · as of 2026-08-03].
What works
- The biologics and drug delivery business, serving pharma customers in preclinical and late-stage trials, is described as 'potentially represents the largest opportunity for growth' [sec_mda · as of 2026-08-03].
- The IRRAS acquisition is expected to grow revenue through a larger combined organization, expanded product offerings, and increased customer reach in the U.S. and internationally [sec_mda · as of 2026-08-03].
- Revenue from disposable products is an important part of the business model, providing recurring income [sec_mda · as of 2026-08-03].
What to weigh
- The company reported a net loss of $11.3M for the quarter ended 2026-06-30 [sec].
- Total debt of $50.2M significantly exceeds shareholders' equity of $19.7M as of 2026-06-30 [sec].
- Growth in the biologics and drug delivery segment depends on pharma customers' successful clinical trials and regulatory approvals, which are uncertain [sec_mda · as of 2026-08-03].
- Future revenue from disposable products is 'difficult to predict' and may not offset ongoing R&D and SG&A expenses [sec_mda · as of 2026-08-03].
From the filings
Quoted directly from source documents.
Biologics and drug delivery is the largest growth opportunity.
“This part of our business potentially represents the largest opportunity for growth”
SEC MD&A · August 3, 2026
Revenue from disposable products is important but unpredictable.
“Future revenue from sales of such products is difficult to predict and may not be sufficient to offset our continuing research and development expenses and our increasing selling, general and administrative expenses.”
SEC MD&A · August 3, 2026
IRRAS acquisition expected to boost revenue.
“As a result of the IRRAS acquisition, revenue is expected to grow over the coming years due to a larger combined organization, expanded product offerings, and increased customer reach, both in the U.S. and internationally.”
SEC MD&A · August 3, 2026
Growth depends on pharma customers' trial success.
“our ability to grow in this market is dependent on our ability to maintain and establish new relationships with pharmaceutical company customers, such customers' continuation of research and product development plans, such customers successfully completing clinical trials and obtaining regulatory approvals of their drugs and biologics”
SEC MD&A · August 3, 2026
Risks & what to watch (4)›
Key risks
- High debt relative to equity — Total debt of $50.2M exceeds shareholders' equity of $19.7M as of 2026-06-30 [sec].
- Continued net losses — Net loss of $11.3M for the quarter ended 2026-06-30 [sec].
- Dependence on pharma partners' success — Growth relies on partners' clinical trial and regulatory outcomes, which are uncertain [sec_mda · as of 2026-08-03].
- Unpredictable disposable product revenue — Future disposable product revenue is difficult to predict and may not cover expenses [sec_mda · as of 2026-08-03].
What to watch
- Progress of pharma partners' gene and cell therapy trials using ClearPoint Neuro products [sec_mda · as of 2026-08-03].
- Revenue growth and integration benefits from the IRRAS acquisition [sec_mda · as of 2026-08-03].
- Trend in cash burn and ability to reduce net losses [sec].
- Changes in debt levels and capital structure [sec].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run ClearPoint Neuro Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ClearPoint Neuro Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
15.3 months
D/E 7.05 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 6 sells (180d)
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
118
Total value held
$122.6M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 2,487,230 | $22.6M |
| blackrock, inc. | 2,082,750 | $19.0M |
| mak capital one llc | 1,901,489 | $17.3M |
| geode capital management, llc | 705,720 | $6.4M |
| state street corp | 679,819 | $6.2M |
| goldman sachs group inc | 463,617 | $4.2M |
| susquehanna international group, llp | 451,484 | $4.1M |
| brown advisory inc | 325,906 | $3.0M |
| vanguard portfolio management llc | 284,809 | $2.6M |
| millennium management llc | 231,974 | $2.1M |
Showing top 10 of 118 institutional holders of ClearPoint Neuro Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 17.1%
- Days to cover
- 10.0
- Shares short
- 4,940,673
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CLPT short interestGovernance
Frequently asked questions
What is the AI investment thesis for ClearPoint Neuro Inc.?
ClearPoint Neuro Inc. is a medical device company focused on products and services for drug delivery into the brain, with a key growth driver in supporting pharmaceutical customers' gene and cell therapy trials.
Who is the CEO of ClearPoint Neuro Inc.?
Mr. Joseph Michael Burnett is the chief executive officer of ClearPoint Neuro Inc. (CLPT).
Where is ClearPoint Neuro Inc. headquartered?
ClearPoint Neuro Inc. (CLPT) is headquartered in Solana Beach, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.